undamentalytics Newsletter
Sign in

Lifevantage Corp (LFVN) stock

Add to watchlist

Add holding +

NASDAQ: LFVN Nasdaq Personal Care Products Next results ~November 9, 2026

C Fundamentals grade

Lifevantage Corp is a US-listed company in the personal care products industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$7.6

Cash-flow model

Base case. Range ~$6.0–$9.7 across our lower- and higher-growth cases (-1%–9% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 29% above it.

Price used: $5.87, November 2, 2026

Lifevantage Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 2 selling8 purchases and 6 sales by directors and officers, last 12 monthsInsider trades
  • Funds40 adding, 61 cuttingOf 19 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Lifevantage files

10-K filed August 27: Lifevantage

Model value −6.4%

Lifevantage's revenue for the twelve months to June 2026 came in at $183m, down 20.1% on a year earlier and a steeper fall than the 12.2% decline seen a quarter earlier. Among the personal care products companies we cover, that ranks 19th of 20 for growth. Free-cash-flow margin, by contrast, held steady at 3.7%. Buybacks have trimmed the diluted share count by 2.2% over the year, lifting the claim each remaining share has on earnings. Our model value has slipped from $8.10 to $7.58 a share, well above the current price of $5.88, so the rating stays Buy. At that price, the market appears to be pricing in cash flow shrinking by about 2.9% a year for five years, not far off the -3.7% a year revenue growth actually delivered.

Source: 10-K filed August 27, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Lifevantage stands after its latest 10-K

Revenue for the twelve months to June 2026 was $183m, down 20.1% on a year earlier, a steeper fall than the 12.2% decline a quarter earlier. Free-cash-flow margin held at 3.7%. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $8.10 a share, against a share price of $5.85.

10-K on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Lifevantage Corp's trailing-twelve-month revenue fell 20.1% year on year, with a free-cash-flow margin of 3.7%. Where it stands out: days sales outstanding of 6 days ranks 1 of 14 personal care products companies we cover. Where it lags: change in growth rate of -8.0pp ranks 21 of 21 personal care products companies we cover.

Our discounted-cash-flow model values the business at ~$7.6 per share in the base case (~$6.0–$9.7 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -20.1% (-8.0pp vs the prior quarter), the 3rd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $5.87 is 29% below our value per share of $8.
  • Shrinking share count. Diluted shares fell 2.2% in a year, so each share owns more of the business.

Things to watch

  • Revenue shrinking. Revenue fell 20.1% over the last 12 months.
  • Growth slowing. The growth rate is 8.0 points lower than a quarter earlier.
  • Volatile shares. Over the past year the shares showed annualised volatility of 74% and a beta of 0.7 against the S&P 500.
  • Gross margin slipping. Gross margin is down 2.8 points on a year ago.
  • Heavily shorted. 10.8% of the shares available to trade are sold short (29.2 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.

Latest results: FY2026 Q4

Filed August 27, 2026
Earnings per share
$0.11 against an average estimate of $0.13: missed by 13.2%
Revenue
$42m, down 23.1% on a year earlier
Share reaction
-3.9% in the first session after the results on August 27, 2026, against +0.4% for the S&P 500
Next report
November 9, 2026; average EPS estimate $0.06

Lifevantage's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.2%
  • 1 week+1.9%
  • 1 month-3.3%
  • This year-2.4%
  • 1 year-26.1%
  • 5 years+1.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$183M
Operating margin
3.3%
Net margin
2.8%
EPS (TTM, diluted)
$0.40

Growth

Revenue growth
−20.1%
Change in growth rate
−8.0 pts
Share count change
−2.2%

Cash

Free cash flow (TTM)
$6.7M
FCF margin
3.7%
Stock pay % of revenue
1.3%

Earnings

Last results
August 27, 2026
Next results (est.)
November 27, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Governance
  2. Results
  3. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Lifevantage Corp valuation models and calculator

What the price is pricing in

The share price implies cash flow shrinking about 2.9% a year for five years.That is close to the -3.7% a year revenue growth Lifevantage has delivered.

  • Priced in-2.9%
  • Last 12 months-20.1%
  • 3 years a year-5.1%
  • 5 years a year-3.7%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($5.88, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$7.6
Price used
$5.88close November 3, 2026
Implied change
▲ +29%
Uncertainty
Low

How we got here: a discounted-cash-flow model of Lifevantage Corp's free cash flow after stock-based pay with after-tax interest added back ($4.7M, FY2026 Q4 TTM), growing -4% and 3.4% in the next two years (forecasts, guidance and its record), then back to 4% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$6.0–~$9.7 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Lifevantage Corp's free cash flow after stock-based pay ( $4.7M, FY2026 Q4 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Lifevantage Corp as an operating company, with every model that fits that kind of business. Cost of equity 7.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.63 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$7.6 ~$6.0–$9.7 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.6 ~$5.7–$9.9 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$5.3 ~$3.9–$7.4 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$6.6 ~$5.5–$8.3 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$6.7 ~$5.3–$7.6 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Lifevantage Corp with Personal Care Products in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −22%
  • Revenue growth 5 points higher ▲ +29%
  • Free-cash-flow margin 1 point lower ▼ −24%
  • Last year's free-cash-flow margin change, if it persists ▼ −19%
  • Discount rate 1 point higher ▼ −13%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $7$9$11$15$19$25
8.5% $5$7$9$11$14$18
10% $5$6$7$9$11$14

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026
Share price$11.58$3.69$5.42$11.05$11.51$6.26$3.73$3.85$6.12$12.64$6.19
Market value$168m$52m$77m$166m$168m$89m$49m$48m$80m$164m$79m
+ Net debt (− = net cash)$2m−$4m−$11m−$17m−$22m−$23m−$20m−$22m−$17m−$20m−$15m
Enterprise value$170m$48m$65m$148m$146m$66m$29m$27m$63m$144m$64m
Multiples
Price / sales 0.8x0.3x0.4x0.7x0.7x0.4x0.2x0.2x0.4x0.7x0.4x
Price / earnings 27.5x32.4x13.3x22.3x14.5x6.9x15.6x19.0x27.1x16.7x15.5x
Price / free cash flow 30.7x9.4x8.9x10.8x10.7x7.1x7.6x12.9x8.0x15.6x11.8x
EV / EBITDA 11.1x7.9x5.6x12.7x8.0x3.1x2.6x3.4x7.9x9.4x7.2x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

74 /100

Strong moat

How hard Lifevantage's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 154.2% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 82.1%, moving by 2.0 percentage points (standard deviation) across 10 years.

  • Durability 7 / 20

    Operating margin has been a median 4.0%; its worst year was 2.0%.

  • Cash conversion 12 / 20

    Free cash flow was positive in 10 of 10 years, at a median 4.4% of revenue.

  • Discipline 20 / 20

    The diluted share count fell 11.0% over five years; stock-based pay has been a median 1.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (79 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $40m and EPS of $0.06 (range $0.03 to $0.10) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.32 −42% $165m −9%
Next $0.39 +20% $168m +1%

Next year's EPS estimate has moved −5.7% in 90 days, across 3 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −29.2% on 90 days ago. In the last 30 days, 1 analyst raised Lifevantage Corp's forecast and 2 cut it.

Consensus EPS forecast Lifevantage Corp, last 90 days
$0.30 $0.35 $0.40 $0.45 $0.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.46 Current fiscal year, 60 days ago: $0.46 Current fiscal year, 30 days ago: $0.46 Current fiscal year, 7 days ago: $0.46 Current fiscal year, Now: $0.32 $0.32 Next fiscal year, 90 days ago: $0.41 Next fiscal year, 60 days ago: $0.41 Next fiscal year, 30 days ago: $0.41 Next fiscal year, 7 days ago: $0.41 Next fiscal year, Now: $0.39 $0.39

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.46$0.41
60 days ago $0.46$0.41
30 days ago $0.46$0.41
7 days ago $0.46$0.41
Now $0.32$0.39

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.13 $0.11 −13.2%
Mar 2026 $0.16 $0.12 −23.4%
Dec 2025 $0.15 $0.15 0.0%
Sept 2025 $0.19 $0.18 −5.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 27, 2026

No numeric guidance in Lifevantage Corp's latest earnings release (filed August 27, 2026). Some companies give their outlook only on the earnings call.

How our valuation uses these forecasts

Our cash-flow model grows Lifevantage Corp's revenue by -4.0% next year and +3.4% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (-9.4%, weight 60%) and the company's own record (+4.0%, weight 40%) . How the weights are set.

Analyst recommendations

2 analysts, Oct 2026
Buy150%
Hold150%
Sell00%

Monthly trend

  1. Oct 2026112
  2. Sep 2026112

Counts of recommendations published by analysts covering Lifevantage Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.8%
of tradable shares
Days to cover
29.19
at average volume
Short interest, 1 month
−14%
to October 15, 2026
Held by institutions
57%
of shares
Held by insiders
13.7%
of shares
Employees
209
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −26.1%

$7.94 on October 31, 2025 to $5.87

ThenNowEffect
Revenue (last 12 months) $229m $183m −20.1%
Net margin 4.3% 2.8% −35.3%
P/E multiple 10.5x 14.7x +39.7%
Share count 13m 13m +2.2%

Biggest factor: net margin.

Last 3 years −17.0%

$7.07 on November 3, 2023 to $5.87

ThenNowEffect
Revenue (last 12 months) $213m $183m −14.4%
Net margin 1.2% 2.8% +133.4%
P/E multiple 35.0x 14.7x −58.0%
Share count 13m 13m −1.1%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
LFVN−32%−40%+75%+197%−64%−2%
Industry peers (median)+32%−32%+3%−11%−34%+1%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
LFVN25%33%42%67%33%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
LFVN−40%−47%−47%−31%−76%−46%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 84% from January 14, 2025 to April 9, 2026. Getting back needed a 521% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.96 – $10.62
From 52-week high
−44.7%
vs 50-day average
−4.5%
vs 200-day average
+0.7%
Volatility (1 year)
74%
Beta vs S&P 500
0.65

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 11 down
typical move ±9.5%
After a week
5 up, 7 down
typical move ±9.8%
After a month
6 up, 6 down
typical move ±23.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 27, 2026 −3.9% +0.4% −6.9% −5.6%
May 6, 2026 −8.6% +1.1% −4.0% +82.8%
February 4, 2026 −13.8% −1.7% −5.0% −8.1%
November 4, 2025 −0.4% −0.8% −10.4% −4.4%
September 4, 2025 −10.8% +0.5% −13.3% −29.9%
May 6, 2025 −5.1% −0.4% +3.0% +5.5%
February 5, 2025 −20.0% +0.8% −18.4% −35.0%
October 29, 2024 −4.2% −0.1% +7.0% +6.7%
August 28, 2024 −11.2% −0.6% +2.9% +49.0%
May 2, 2024 +6.3% +2.2% +10.0% +28.5%
January 30, 2024 −8.9% −1.7% +3.8% +17.6%
November 9, 2023 −21.2% +0.8% −32.3% −5.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Lifevantage Corp’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade C (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Lifevantage Corp in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Lifevantage Corp
$180M $200M $220M $240M FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue (TTM), FY24 Q1: $213M Revenue (TTM), FY24 Q2: $211M Revenue (TTM), FY24 Q3: $205.5M Revenue (TTM), FY24 Q4: $200.2M Revenue (TTM), FY25 Q1: $196M Revenue (TTM), FY25 Q2: $212.2M Revenue (TTM), FY25 Q3: $222.3M Revenue (TTM), FY25 Q4: $228.5M Revenue (TTM), FY26 Q1: $228.9M Revenue (TTM), FY26 Q2: $210M Revenue (TTM), FY26 Q3: $195.3M Revenue (TTM), FY26 Q4: $182.6M $182.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $213M
FY24 Q2 $211M
FY24 Q3 $205.5M
FY24 Q4 $200.2M
FY25 Q1 $196M
FY25 Q2 $212.2M
FY25 Q3 $222.3M
FY25 Q4 $228.5M
FY26 Q1 $228.9M
FY26 Q2 $210M
FY26 Q3 $195.3M
FY26 Q4 $182.6M
Revenue growth, TTM YoY Lifevantage Corp
-30% -20% -10% 0% 10% 20% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue growth, TTM YoY, FY24 Q1: 3.9% Revenue growth, TTM YoY, FY24 Q2: 2.2% Revenue growth, TTM YoY, FY24 Q3: -2.2% Revenue growth, TTM YoY, FY24 Q4: -6.2% Revenue growth, TTM YoY, FY25 Q1: -8.0% Revenue growth, TTM YoY, FY25 Q2: 0.6% Revenue growth, TTM YoY, FY25 Q3: 8.2% Revenue growth, TTM YoY, FY25 Q4: 14.2% Revenue growth, TTM YoY, FY26 Q1: 16.8% Revenue growth, TTM YoY, FY26 Q2: -1.0% Revenue growth, TTM YoY, FY26 Q3: -12.2% Revenue growth, TTM YoY, FY26 Q4: -20.1% -20.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 3.9%
FY24 Q2 2.2%
FY24 Q3 -2.2%
FY24 Q4 -6.2%
FY25 Q1 -8.0%
FY25 Q2 0.6%
FY25 Q3 8.2%
FY25 Q4 14.2%
FY26 Q1 16.8%
FY26 Q2 -1.0%
FY26 Q3 -12.2%
FY26 Q4 -20.1%
Operating margin (TTM) Lifevantage Corp
0% 2% 4% 6% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Operating margin (TTM), FY24 Q1: 1.7% Operating margin (TTM), FY24 Q2: 1.7% Operating margin (TTM), FY24 Q3: 2.0% Operating margin (TTM), FY24 Q4: 2.2% Operating margin (TTM), FY25 Q1: 3.1% Operating margin (TTM), FY25 Q2: 5.1% Operating margin (TTM), FY25 Q3: 5.8% Operating margin (TTM), FY25 Q4: 5.3% Operating margin (TTM), FY26 Q1: 5.2% Operating margin (TTM), FY26 Q2: 4.3% Operating margin (TTM), FY26 Q3: 3.4% Operating margin (TTM), FY26 Q4: 3.3% 3.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q1 1.7%
FY24 Q2 1.7%
FY24 Q3 2.0%
FY24 Q4 2.2%
FY25 Q1 3.1%
FY25 Q2 5.1%
FY25 Q3 5.8%
FY25 Q4 5.3%
FY26 Q1 5.2%
FY26 Q2 4.3%
FY26 Q3 3.4%
FY26 Q4 3.3%
FCF margin (TTM) Lifevantage Corp
0% 2% 4% 6% 8% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 FCF margin (TTM), FY24 Q1: 4.4% FCF margin (TTM), FY24 Q2: 5.0% FCF margin (TTM), FY24 Q3: 5.3% FCF margin (TTM), FY24 Q4: 5.0% FCF margin (TTM), FY25 Q1: 2.7% FCF margin (TTM), FY25 Q2: 6.1% FCF margin (TTM), FY25 Q3: 5.4% FCF margin (TTM), FY25 Q4: 4.6% FCF margin (TTM), FY26 Q1: 3.8% FCF margin (TTM), FY26 Q2: 0.8% FCF margin (TTM), FY26 Q3: 1.9% FCF margin (TTM), FY26 Q4: 3.7% 3.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q1 4.4%
FY24 Q2 5.0%
FY24 Q3 5.3%
FY24 Q4 5.0%
FY25 Q1 2.7%
FY25 Q2 6.1%
FY25 Q3 5.4%
FY25 Q4 4.6%
FY26 Q1 3.8%
FY26 Q2 0.8%
FY26 Q3 1.9%
FY26 Q4 3.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2026, from the 10-K

Each dollar Lifevantage took in during FY2026, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $183M
  2. Cost of revenue $41M · 22.4%
  3. Gross profit $142M · 77.6%
  4. Research and development $1M · 0.5%
  5. Selling, general and admin $58.4M · 32.0%
  6. Other operating costs $76.1M · 41.7%
  7. Operating income $6.1M · 3.3%
  8. Income tax $994,000 · 0.5%
  9. Net income $5.1M · 2.8%

Shares of revenue. Source: Lifevantage's 10-K for FY2026, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Jun 2011 2012 Jun 2012 2013 Jun 2013 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 2026 Jun 2026
Income
Revenue 39 126 208 214 190 207 199 203 226 233 220 206 213 200 229 183
Gross profit 33 108 172 181 162 173 166 168 188 195 182 168 170 159 184 142
EBITDA 4 22 14 22 16 15 6 12 12 18 21 11 8 8 15 9
Operating income 4 21 12 19 14 13 4 10 10 15 18 8 4 4 12 6
Net income −51 12 8 11 7 6 2 6 7 12 13 3 3 3 10 5
Diluted EPS −$4.83 $0.77 $0.42 $0.71 $0.50 $0.42 $0.11 $0.41 $0.50 $0.79 $0.90 $0.24 $0.20 $0.23 $0.75 $0.40
Growth (year on year)
Revenue — +224.2% +65.0% +2.8% −11.0% +8.5% −3.4% +1.9% +11.2% +3.1% −5.5% −6.3% +3.4% −6.2% +14.2% −20.1%
EBITDA — +461.1% −37.5% +57.1% −25.0% −5.4% −60.2% +91.2% +0.5% +55.8% +15.5% −48.6% −27.7% +1.0% +94.0% −42.2%
Operating income — +479.6% −43.8% +61.2% −28.5% −3.5% −66.8% +132.0% −4.9% +57.6% +13.9% −57.0% −43.8% — +181.6% −50.0%
Net income — — −39.0% +49.6% −37.4% −14.3% −73.7% — +29.0% +55.5% +11.6% −75.8% — — — −48.3%
Diluted EPS — — −45.5% +69.0% −29.6% −16.0% −73.8% — +22.0% +58.0% +13.9% −73.3% — — — −46.7%
Margins
Gross margin 84.8% 85.7% 82.4% 84.5% 85.3% 83.6% 83.2% 82.9% 83.2% 83.7% 82.7% 81.5% 79.7% 79.3% 80.4% 77.6%
EBITDA margin 10.1% 17.4% 6.6% 10.1% 8.5% 7.4% 3.1% 5.7% 5.2% 7.8% 9.6% 5.3% 3.7% 4.0% 6.7% 4.9%
Operating margin 9.5% 17.0% 5.8% 9.1% 7.3% 6.5% 2.2% 5.1% 4.3% 6.6% 8.0% 3.7% 2.0% 2.2% 5.3% 3.3%
Net margin −130.5% 9.9% 3.7% 5.3% 3.7% 3.0% 0.8% 2.8% 3.3% 5.0% 5.9% 1.5% 1.2% 1.5% 4.3% 2.8%
Free-cash-flow margin 11.7% 13.6% 2.7% 4.8% 6.3% 2.7% 2.8% 4.2% 6.8% 6.7% 5.7% 3.1% 1.8% 5.0% 4.6% 3.7%
Cash flow
Cash from operations 5 19 11 12 13 6 7 13 18 18 16 8 7 12 12 10
Capital spending 0 2 5 2 1 1 1 5 3 3 4 2 3 2 1 4
Free cash flow 5 17 6 10 12 5 6 9 15 16 13 6 4 10 11 7
Stock-based pay 1 1 2 3 2 3 3 3 6 5 2 2 3 3 6 2
Free cash flow after stock pay 4 16 3 7 10 3 3 5 10 11 10 5 1 7 5 4
Balance sheet
Cash 6 25 26 20 14 8 11 17 19 22 23 20 22 17 20 15
Total debt 0 0 0 31 22 10 8 6 1 — 0 0 0 0 0 0
Net debt (negative = net cash) −6 −25 −26 10 8 2 −4 −11 −17 −22 −23 −20 −22 −17 −20 −15
Diluted shares 10m 17m 18m 16m 14m 15m 14m 14m 15m 15m 14m 13m 13m 13m 13m 13m
Returned to shareholders
Dividends — — — — — — — — — 0 0 0 2 7 2 2
Buybacks 0 1 7 46 10 0 0 2 5 5 12 9 1 6 3 2
Total returned 0 1 7 46 10 0 0 2 5 5 12 9 2 13 5 4

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $62m
Short-term assets $38mLonger-term assets $24m
What it owes, and who funded it · $62m
Short-term liabilities $20mLonger-term liabilities $8mShareholders' equity $34m
  • Short-term assets cover short-term liabilities $38m of assets due within a year against $20m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $38m short-term assets against $8m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Lifevantage Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q4 TTM
Buybacks (TTM)
$2M
Dividends (TTM)
$2.3M
Returned to shareholders
66%
of free cash flow
Buybacks, last 3 fiscal years
$11.6M
Diluted share count
−2.2%
year over year
Total shareholder yield
6.0%
dividends 3.2% + buybacks 2.8% of market value
Dividend payout ratio
46%
of net income paid out
R&D spending
0.5%
of revenue
Sales & admin spending
32.0%
of revenue
Days sales outstanding
6 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in personal care products
Last 12 months unless stated LFVN MTEX HNST NATR ODD USNA Median
Revenue, last 12 months $183m $107m $342m $492m $810m $913m $913m
Revenue growth, last 12 months −20.1% −5.0% −12.3% 6.8% 25.2% 1.6% 3.5%
Revenue growth, 3-year average −5.1% −7.7% 0.8% 4.4% — −1.2% −0.1%
Revenue growth, latest quarter −23.1% 3.8% −10.9% 1.9% — −5.3% 2.7%
Gross margin 77.6% 76.1% 35.7% 73.2% 72.7% 77.4% 69.2%
Operating margin 3.3% 2.5% −4.4% 6.0% 14.7% −0.1% 6.7%
Operating margin, 3-year average 3.6% 0.4% −2.2% 5.1% — 5.3% 5.5%
Net margin 2.8% −6.9% −3.6% 3.7% 13.7% −2.4% 3.4%
Cash from operations / revenue 5.6% 2.3% 16.5% 5.6% 10.8% 3.0% 9.9%
Free-cash-flow margin 3.7% 1.5% 15.4% 3.7% 10.3% 1.7% 9.6%
Free-cash-flow margin, 3-year average 4.4% −1.0% 6.3% 4.0% — 4.7% 6.0%
Stock pay / revenue 1.3% 0.4% 3.2% 1.3% 4.2% 1.6% 1.0%
Change in share count −2.2% 1.2% 1.8% −4.6% — −2.9% −0.0%

Median of all 21 companies we cover in personal care products. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

21 personal care products companies
Measure Company Peer median Rank
Revenue growth Growth -20.1% 3.5% 20 of 21
Change in growth rate Growth -8.0pp +0.7pp 21 of 21
Gross margin Profitability 77.6% 69.2% 2 of 21
Operating margin Profitability 3.3% 6.7% 13 of 21
Net margin Profitability 2.8% 3.4% 12 of 21
Free-cash-flow margin Cash generation 3.7% 9.6% 15 of 21
Stock pay as % of revenue Cash generation 1.3% 1.0% 11 of 18
Change in share count Balance sheet -2.2% -0.0% 7 of 19
Days sales outstanding Balance sheet 6 days 33 days 1 of 14

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to June 30, 2026
Products and services
Line of business Revenue YoY
Protandim $82M ▼ 14.0%
True Science Product Line $37.9M ▼ 22.3%
Life Vantage Product Line $32.3M ▼ 47.4%
AXIO Product Line $15M ▼ 2.0%
Love Biome Product Line $9.1M —
Other $4.4M ▼ 23.3%
Phys IQ Product Line $3.8M ▼ 25.5%
Petandim Product Line $2M ▼ 7.4%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
United States $135M 74.2% ▼ 24.1%
Outside the US $47.2M 25.8% ▼ 5.8%
Japan $24.1M 51.2% ▼ 4.9%
Other Foreign $23M 48.8% ▼ 6.7%

From Lifevantage Corp's 10-K filed August 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$36.8M
Institutions reporting
88
Shares held vs prior quarter
▼ 22.1%
Positions opened / closed
17 / 29

Top buyers and sellers, Q2 2026: 40 institutions bought and 61 sold ; the biggest buyer was Susquehanna International Group, LLP (+169K shares) and the biggest seller Capital Management Corp (−564K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Capital Management Corp $11.7M 1.9M 31.8% ▼ 23.1%
Renaissance Technologies LLC $4.2M 669K 11.3% ▼ 22.9%
Vanguard Capital Management LLC $2.7M 429K 7.3% ▼ 0.1%
Blackrock, Inc. $1.7M 269K 4.6% ▼ 65.1%
Dimensional Fund Advisors LP $1.6M 256K 4.3% ▼ 7.2%
Envestnet Asset Management Inc $1.4M 230K 3.9% ▲ 4.9%
Susquehanna International Group, LLP $1.1M 169K 2.9% New
American Century Companies Inc $900,969 144K 2.4% ▲ 38.0%
Jane Street Group, LLC $861,470 138K 2.3% New
Geode Capital Management, LLC $754,305 121K 2.0% ▼ 53.7%
AQR Capital Management LLC $706,389 113K 1.9% ▼ 27.5%
Goldman Sachs Group Inc $691,791 111K 1.9% ▼ 40.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Lifevantage Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $195,983 8 trades by 2 insiders, last 12 months Insider sales History → $471,616 6 trades by 2 insiders · 0% under pre-set plans
Net ▼ $275,633 net selling
Insider Date Trade Shares Price Value
Lewis Darwin Director September 15, 2026 Buy pre-set plan 976 $6.22 $6,071
Cunningham Kristen Chief Sales Officer September 14, 2026 Sell 8,901 $6.18 $55,008
Cunningham Kristen Chief Sales Officer September 11, 2026 Sell 100 $6.41 $641
Lewis Darwin Director June 15, 2026 Buy pre-set plan 705 $8.60 $6,063
Beindorff Michael A Director June 3, 2026 Sell 10,000 $8.55 $85,500
Lewis Darwin Director March 16, 2026 Buy pre-set plan 1,055 $5.23 $5,518
Dayton Judd Director March 2, 2026 Buy 10,500 $4.53 $47,565
Dayton Judd Director February 27, 2026 Buy 18,097 $4.63 $83,789
Dayton Judd Director February 26, 2026 Buy 4,600 $4.58 $21,068
Lewis Darwin Director February 9, 2026 Buy 3,955 $5.22 $20,645
Lewis Darwin Director December 15, 2025 Buy pre-set plan 805 $6.54 $5,265
Beindorff Michael A Director November 19, 2025 Sell 12,607 $6.42 $80,937

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 27, 2026 estimated from the company's past filing pattern, not announced

  • August 27, 2026
  • May 6, 2026
  • February 4, 2026
  • November 4, 2025
  • September 4, 2025
  • May 6, 2025

Recent SEC filings

Data status

When each part of this page on Lifevantage Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Lifevantage Corp in brief

What does Lifevantage Corp do?
Lifevantage Corp is a US-listed company in the personal care products industry. Its financial year ends in June.
What is Lifevantage Corp's stock ticker?
Lifevantage Corp trades under the ticker LFVN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Lifevantage Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Lifevantage Corp reported revenue of $183M, 20.1% lower than a year earlier, according to its SEC filings.
What is Lifevantage Corp's free cash flow?
Lifevantage Corp's free-cash-flow margin is 3.7% of revenue over the trailing twelve months, ranking 15 of the 21 personal care products companies we cover.
What is Lifevantage Corp's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Lifevantage Corp's free cash flow after stock-based pay gives ~$7.6 per share in the base case, and ~$6.0–$9.7 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Lifevantage Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Capital Management Corp, Renaissance Technologies LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Lifevantage Corp buying back stock, and does it pay a dividend?
Lifevantage Corp spent $2M on share repurchases over the trailing twelve months, and its diluted share count fell 2.2% over the year.
What is Lifevantage Corp's market cap?
On June 30, 2026, Lifevantage Corp's market capitalisation was about $78.6M, with a price-to-earnings ratio of 15.5 and net debt of -$14.9M. Market figures come from third-party market data and may be delayed.
Does Lifevantage Corp pay a dividend?
Yes: Lifevantage Corp paid $2.3M in dividends over the trailing twelve months, a dividend yield of 3.19% and a payout ratio of 46.2%.
Who are Lifevantage Corp's competitors?
In our Personal Care Products peer group, the companies closest to Lifevantage Corp are Mannatech Inc, Honest Company, Inc., Natures Sunshine Products Inc, Oddity Tech Ltd and Usana Health Sciences Inc. The side-by-side comparison below sets their revenue, margins and growth against Lifevantage Corp's.
Are insiders buying or selling Lifevantage Corp stock?
Over the last 12 months, Lifevantage Corp's directors and officers reported 8 open-market purchases and 6 sales on Form 4. The insider trading page charts every trade.
When is Lifevantage Corp's next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Lifevantage Corp announces its own schedule.